Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial

Michael E Weinblatt; Clifton O Bingham; Alan M Mendelsohn; Lilianne Kim; Michael Mack; Jiandong Lu; Daniel Baker; Rene Westhovens

doi:10.1136/annrheumdis-2012-201411

Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-201411 ◽

2012 ◽

Vol 72 (3) ◽

pp. 381-389 ◽

Cited By ~ 60

Author(s):

Michael E Weinblatt ◽

Clifton O Bingham ◽

Alan M Mendelsohn ◽

Lilianne Kim ◽

Michael Mack ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Methotrexate Therapy ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

FRI0169 Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with results observed by 2 weeks: Results of the phase 3, multicenter, double-blind, placebo-controlled trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.2626 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 368.3-369

Author(s):

M.E. Weinblatt ◽

C.O. Bingham ◽

A.M. Mendelsohn ◽

L. Kim ◽

M. Mack ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Controlled Trial ◽

Methotrexate Therapy ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-203742 ◽

2013 ◽

Vol 73 (12) ◽

pp. 2152-2159 ◽

Cited By ~ 18

Author(s):

Michael E Weinblatt ◽

Rene Westhovens ◽

Alan M Mendelsohn ◽

Lilianne Kim ◽

Kim Hung Lo ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Clinical Benefit ◽

Active Rheumatoid Arthritis ◽

Methotrexate Therapy ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727328077.793564275 ◽

2019 ◽

Author(s):

Ladislav Senolt

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Parallel Group

Download Full-text

OP0025 Results from a multicenter, international, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.1708 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 61.1-61 ◽

Cited By ~ 4

Author(s):

B. Hsu ◽

S. Sheng ◽

M.E. Weinblatt ◽

J.S. Smolen

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Methotrexate Therapy ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study

Arthritis Research & Therapy ◽

10.1186/s13075-015-0516-6 ◽

2015 ◽

Vol 17 (1) ◽

Cited By ~ 28

Author(s):

Josef S Smolen ◽

Jonathan Kay ◽

Mittie Doyle ◽

Robert Landewé ◽

Eric L Matteson ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Α ◽

Active Rheumatoid Arthritis ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Α ◽

Necrosis Factor

Download Full-text

Results of A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of The Efficacy And Safety of Sirukumab, An Anti-IL-6 Cytokine Monoclonal Antibody, In Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment (Sirround-D)

Value in Health ◽

10.1016/j.jval.2016.09.1074 ◽

2016 ◽

Vol 19 (7) ◽

pp. A531 ◽

Cited By ~ 2

Author(s):

T Takeuchi ◽

C Thorne ◽

G Karpouzas ◽

S Sheng ◽

W Xu ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Disease Modifying ◽

Rheumatic Drug

Download Full-text

Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study

The Lancet ◽

10.1016/s0140-6736(17)30401-4 ◽

2017 ◽

Vol 389 (10075) ◽

pp. 1206-1217 ◽

Cited By ~ 53

Author(s):

Daniel Aletaha ◽

Clifton O Bingham ◽

Yoshiya Tanaka ◽

Prasheen Agarwal ◽

Regina Kurrasch ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Parallel Group

Download Full-text

THU0100 Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.2065 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 188.1-188 ◽

Cited By ~ 4

Author(s):

B. Hsu ◽

S. Sheng ◽

J.S. Smolen ◽

M.E. Weinblatt

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Methotrexate Therapy ◽

Phase 2 ◽

Proof Of Concept ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Dose Ranging

Download Full-text

Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study

Rheumatology and Therapy ◽

10.1007/s40744-017-0086-y ◽

2017 ◽

Vol 4 (2) ◽

pp. 475-488 ◽

Cited By ~ 15

Author(s):

Hasan Tahir ◽

Atul Deodhar ◽

Mark Genovese ◽

Tsutomu Takeuchi ◽

Jacob Aelion ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1164186.624873 ◽

2009 ◽

Author(s):

Ladislav Senolt

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Jak Inhibitor ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo

Download Full-text